Aquila Bioscience, a University of Galway spin-out is collaborating with the European Space Agency (ESA) to develop a nature-inspired pathogen decontamination technology for safer space exploration.
The company explained how traditional antimicrobial measures, while effective on Earth, present significant limitations in space due to potential toxicity, pathogen resistance, and long-term stability concerns.
It said the conditions of spaceflight elevate the risk of infectious diseases by altering both human and microbial physiology.
Professor Lokesh Joshi, Founder of Aquila Bioscience and Stokes Professor of Glycosciences at University of Galway, said the company is committed to addressing the challenges of pathogen exposure in space.
"Our Pathogen Capturing Technology aligns with the principles of safety, sustainability and innovation that are essential for the future of space exploration," he said.
"We are honoured to have the European Space Agency's support as we push the boundaries of innovation.
"This collaboration underscores the importance of developing sustainable, non-toxic and effective solutions for challenges associated with space exploration," he added.
